News & Updates

Show Multimedia Only

Avelumab with paclitaxel plus ramucirumab shows promise in esophagogastric adenocarcinoma

27 Jan 2024

Combining the programmed cell death ligand 1 (PDL-1) inhibitor avelumab with paclitaxel plus ramucirumab appears to be efficacious and safe in the second-line treatment of metastatic esophagogastric adenocarcinoma, as shown in the phase II nonrandomized RAP trial.

Avelumab with paclitaxel plus ramucirumab shows promise in esophagogastric adenocarcinoma

27 Jan 2024

Low-dose on par with high-dose calcium supplementation in preventing pre-eclampsia

27 Jan 2024 by

Low-dose calcium supplementation during pregnancy was noninferior to standard high-dose supplementation in preventing the risk of pre-eclampsia, according to two randomized clinical trials conducted in India and Tanzania.

Low-dose on par with high-dose calcium supplementation in preventing pre-eclampsia

27 Jan 2024

Low-dose edoxaban beneficial in older AF patients with extremely low body weight

26 Jan 2024 by

In the treatment of older patients with nonvalvular atrial fibrillation (AF) who are considered ineligible for oral anticoagulants at the recommended therapeutic strength or the approved doses, the use of low-dose edoxaban helps reduce the risk of stroke or systemic embolism regardless of body weight, although this benefit comes with a slightly higher major bleeding events, according to the subgroup analysis of the phase III ELDERCARE‐AF trial.

Low-dose edoxaban beneficial in older AF patients with extremely low body weight

26 Jan 2024

Early sacubitril/valsartan initiation after cardiac bypass surgery safe, effective

26 Jan 2024

For patients who have undergone coronary artery bypass graft, initiating treatment with sacubitril/valsartan early is safe and appears to improve outcomes, as shown in an open-label study.

Early sacubitril/valsartan initiation after cardiac bypass surgery safe, effective

26 Jan 2024

Dupilumab delivers on its promise for Asians with atopic dermatitis

25 Jan 2024 by

Singaporeans who have been treated with dupilumab in real-world clinical setting achieve improvements in the signs and symptoms of moderate-to-severe atopic dermatitis, as shown in a retrospective study.

Dupilumab delivers on its promise for Asians with atopic dermatitis

25 Jan 2024

Cetuximab stored in vials, bags for days remains stable

25 Jan 2024 by

A recent study has demonstrated the extended physicochemical stability of cetuximab in opened vials and infusion bags, which can help save costs for healthcare providers.

Cetuximab stored in vials, bags for days remains stable

25 Jan 2024

GnRHa therapy does not decrease BMD in children with congenital adrenal hyperplasia

25 Jan 2024

Gonadotropin-releasing hormone analogue (GnRHa) therapy is not responsible for the reduction in bone mineral density (BMD) among children with congenital adrenal hyperplasia (CAH), reports a study

GnRHa therapy does not decrease BMD in children with congenital adrenal hyperplasia

25 Jan 2024

Low-dose morphine relieves cough in idiopathic pulmonary fibrosis

24 Jan 2024

In patients with idiopathic pulmonary fibrosis-related cough, treatment with low-dose controlled-release morphine leads to reduced daytime cough frequency and better quality of life, according to data from the phase II PACIFY COUGH crossover trial.

Low-dose morphine relieves cough in idiopathic pulmonary fibrosis

24 Jan 2024

Vaccinated children less likely to experience lingering COVID-19 symptoms

24 Jan 2024 by

SARS-CoV-2 vaccination appears to confer protection against long COVID in the paediatric population, with the protective benefit being stronger in teens.

Vaccinated children less likely to experience lingering COVID-19 symptoms

24 Jan 2024

Isotretinoin use carries no risk of self-harm

23 Jan 2024

Isotretinoin users do not appear to have an elevated risk of self-harm, with the risk of suicide attempts being lower at 2 to 4 years after treatment, according to the results of a meta-analysis.

Isotretinoin use carries no risk of self-harm

23 Jan 2024

News & Updates

Showing Pharmacy articles

Showing

Specialty:

Avelumab with paclitaxel plus ramucirumab shows promise in esophagogastric adenocarcinoma

Avelumab with paclitaxel plus ramucirumab shows promise in esophagogastric adenocarcinoma

Low-dose on par with high-dose calcium supplementation in preventing pre-eclampsia

Low-dose on par with high-dose calcium supplementation in preventing pre-eclampsia

Low-dose edoxaban beneficial in older AF patients with extremely low body weight

Low-dose edoxaban beneficial in older AF patients with extremely low body weight

Early sacubitril/valsartan initiation after cardiac bypass surgery safe, effective

Early sacubitril/valsartan initiation after cardiac bypass surgery safe, effective

Dupilumab delivers on its promise for Asians with atopic dermatitis

Dupilumab delivers on its promise for Asians with atopic dermatitis

Cetuximab stored in vials, bags for days remains stable

Cetuximab stored in vials, bags for days remains stable

GnRHa therapy does not decrease BMD in children with congenital adrenal hyperplasia

GnRHa therapy does not decrease BMD in children with congenital adrenal hyperplasia

Low-dose morphine relieves cough in idiopathic pulmonary fibrosis

Low-dose morphine relieves cough in idiopathic pulmonary fibrosis

Vaccinated children less likely to experience lingering COVID-19 symptoms

Vaccinated children less likely to experience lingering COVID-19 symptoms

Isotretinoin use carries no risk of self-harm

Isotretinoin use carries no risk of self-harm